FDA issues complete response letter regarding QRxPharma’s Moxduo NDA
FDA stated that currently there is no sufficient evidence to support approval of QRxPharma’s pain drug Moxduo. According to FDA, clinical information showing a clear benefit over oxycodone
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.